- Trametinib
- Dabrafenib
- Ivosidenib
- Mirdametinib
Low-grade Glioma Market size was valued at USD 1,439.8 million in 2023 and is expected to grow at an 5.3% CAGR from 2024 to 2030. Low-grade Glioma (low-grade glioma) refers to slow-growing brain tumors originating from glial cells, typically classified as Grade I or II by the World Health Organization. The global low-grade glioma market is driven by increasing incidence rates, advancements in diagnostic technologies, and growing research into targeted therapies. Recent statistics indicate that low-grade gliomas account for approximately 15-20% of all primary brain tumors, with an estimated incidence rate of 1-3 cases per 100,000 people annually. The market has seen significant growth, with the global brain tumor therapeutics market, including low-grade gliomas. Advancements in imaging technologies, particularly high-resolution MRI and PET scans, have improved early detection and monitoring of low-grade gliomas. A 2023 study reported that advanced imaging techniques could detect low-grade gliomas up to 18 months earlier than conventional methods, potentially improving treatment outcomes.
Key opportunities include the development of personalized treatment approaches and the potential for immunotherapies. Clinical trials for low-grade glioma treatments have increased over the past five years, with a particular focus on targeted therapies and immunotherapies. The adoption of precision medicine approaches has led to more tailored treatment plans, with a 2024 meta-analysis reporting a 30% improvement in progression-free survival for patients receiving molecularly targeted therapies compared to standard treatments. However, the market faces challenges such as the complexities of brain tumor treatment and the high cost of novel therapies. Moreover, despite these advancements, significant unmet needs remain in the low-grade glioma market. The heterogeneity of these tumors presents challenges for developing universally effective treatments, and there is a growing emphasis on addressing the long-term cognitive and quality-of-life impacts of both the disease and its treatments. Current trends include a shift towards molecular profiling for more accurate diagnosis and treatment planning, increased focus on quality-of-life outcomes, and the exploration of combination therapies.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The Low-grade Glioma market is primarily driven by increasing incidence rates and advancements in diagnostic technologies. This increase is also attributed to factors such as aging populations and increased exposure to environmental risk factors. Advancements in diagnostic technologies, particularly in molecular profiling and imaging techniques, have revolutionized low-grade glioma detection and classification. The adoption of next-generation sequencing for identifying genetic mutations has improved diagnostic accuracy. Additionally, high-resolution MRI techniques have enhanced the ability to detect small tumors and monitor growth patterns, leading to earlier interventions and potentially improved outcomes. These dynamics are fostering a more personalized approach to low-grade glioma management, driving market growth through increased demand for advanced diagnostic services and targeted therapies.
Low-grade Glioma Market was valued at USD 1,439.8 million in 2023 and is expected to grow at an 5.3% CAGR from 2024 to 2030.
Novartis AG, Pfizer Inc., AstraZeneca plc, Merck & Co., Inc., Roche Holding AG, Bristol-Myers Squibb Company, Eli Lilly and Company, and Bayer AG are some of the major players operating in the low-grade glioma market.
Asia Pacific is estimated to grow at the highest CAGR over the forecast period.
North America accounts for the largest market share and is expected to be the primary market driver in the low-grade glioma market.
Key challenges include the slow growth of tumors, the blood-brain barrier limiting drug delivery, tumor heterogeneity, and balancing treatment efficacy with long-term quality of life.
1.Executive Summary |
2.Global Low-grade Glioma Market Introduction |
2.1.Global Low-grade Glioma Market - Taxonomy |
2.2.Global Low-grade Glioma Market - Definitions |
2.2.1.Drug Type |
2.2.2.Route of Administration |
2.2.3.Distribution Channel |
2.2.4.Region |
3.Global Low-grade Glioma Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Low-grade Glioma Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Low-grade Glioma Market By Drug Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Trametinib |
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Dabrafenib |
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Ivosidenib |
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Mirdametinib |
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6.Global Low-grade Glioma Market By Route of Administration , 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Topical |
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Oral |
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7.Global Low-grade Glioma Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Online Pharmacies |
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Hospital Pharmacies |
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Retail Pharmacies |
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Low-grade Glioma Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Low-grade Glioma Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Drug Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Trametinib |
9.1.2.Dabrafenib |
9.1.3.Ivosidenib |
9.1.4.Mirdametinib |
9.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Topical |
9.2.2.Oral |
9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Online Pharmacies |
9.3.2.Hospital Pharmacies |
9.3.3.Retail Pharmacies |
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Low-grade Glioma Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Trametinib |
10.1.2.Dabrafenib |
10.1.3.Ivosidenib |
10.1.4.Mirdametinib |
10.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Topical |
10.2.2.Oral |
10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Online Pharmacies |
10.3.2.Hospital Pharmacies |
10.3.3.Retail Pharmacies |
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Low-grade Glioma Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Trametinib |
11.1.2.Dabrafenib |
11.1.3.Ivosidenib |
11.1.4.Mirdametinib |
11.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Topical |
11.2.2.Oral |
11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Online Pharmacies |
11.3.2.Hospital Pharmacies |
11.3.3.Retail Pharmacies |
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Low-grade Glioma Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Trametinib |
12.1.2.Dabrafenib |
12.1.3.Ivosidenib |
12.1.4.Mirdametinib |
12.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Topical |
12.2.2.Oral |
12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Online Pharmacies |
12.3.2.Hospital Pharmacies |
12.3.3.Retail Pharmacies |
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Low-grade Glioma Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Trametinib |
13.1.2.Dabrafenib |
13.1.3.Ivosidenib |
13.1.4.Mirdametinib |
13.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Topical |
13.2.2.Oral |
13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Online Pharmacies |
13.3.2.Hospital Pharmacies |
13.3.3.Retail Pharmacies |
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Novartis AG |
14.2.2.Pfizer Inc. |
14.2.3.AstraZeneca plc |
14.2.4.Merck & Co., Inc. |
14.2.5.Roche Holding AG |
14.2.6.Bristol-Myers Squibb Company |
14.2.7.Eli Lilly and Company |
14.2.8.Bayer AG |
14.2.9.Sanofi S.A. |
14.2.10.GlaxoSmithKline plc |
14.2.11.AbbVie Inc. |
14.2.12.Johnson & Johnson |
14.2.13.Takeda Pharmaceutical Company Limited |
15. Research Methodology |
16. Appendix and Abbreviations |